The US Food and Drug Administration granted accelerated approval on 30 October 2026 to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd, Inovio Pharmaceuticals) for adults with recurrent respiratory papillomatosis. It is described as the first plasmid DNA-based immunotherapy approved in the United States. The regulatory label is notable, but the clinical problem is more useful for understanding the decision.
RRP is a rare disease in which human papillomavirus types 6 and 11 drive wart-like growths in the airway, most often on the vocal cords. Excision removes the growths, not the virus, so many patients return to the operating room repeatedly, sometimes for years. Inovio describes the approved indication as reducing the frequency of surgical papilloma excisions. That sounds modest until you consider what repeated airway surgery costs in time, voice, work and recovery.
What the trial measured
The FDA's stated basis was an open-label, multicenter trial of 32 adults who had needed two or more laryngotracheal papilloma surgeries in the previous 12 months, including one scheduled at entry. Among 26 patients with at least three baseline surgeries, 7, or 27 percent, needed no surgical intervention in the first year after treatment. Inovio gives the 95 percent confidence interval as 12 to 48 percent and the median number of prior excisions in that group as 4.5.
Those details matter. The 27 percent is not 27 percent of all 32 enrollees; it is 7 of 26 in a heavily pretreated evaluable group. A confidence interval running from 12 to 48 percent is wide, which is what happens when the denominator is small. The estimate is compatible with a surgery-free year for roughly one in eight patients or nearly one in two. One extra patient would move the percentage by almost four points. That does not make the result meaningless. It makes it provisional.
The endpoint is also a surrogate. The FDA treated surgery frequency as an intermediate endpoint reasonably likely to predict clinical benefit. In plain terms, the agency accepted fewer operations as a stand-in for clinical benefit, rather than requiring that benefit to be measured directly before approval. A surgery-free year is a real, countable event. It is not the same as viral clearance, and it does not by itself prove that the underlying papilloma disease has changed course.
The confirmatory work still owed
Accelerated approval is not the end of the evidence trail. Inovio must run a confirmatory trial. The company says it will submit a draft protocol by the end of 2026 and aims for final protocol alignment by mid-2027. Those are protocol milestones, not results. The public timeline so far covers protocol steps, not the trial's size, design or completion date, so the central question remains open: whether a larger or controlled study will reproduce the surgery-free signal.
The delivery routine is part of the product's identity. Patients first have standard surgical debulking, then a nine-week dosing course by intramuscular injection with the Cellectra 5PSP device. The device uses brief electrical pulses, or electroporation, to help the plasmids enter cells. This is not a take-home pill or a simple office shot. It requires the device and a period of post-injection observation.
Two options, not a league table
Voceryq is the second immunotherapy for adult RRP. The FDA approved Precigen's Papzimeos (zopapogene imadenovec-drba), an adenoviral vector immunotherapy, on 14 August 2025. In its single-arm pivotal cohort of 35 adults who needed three or more surgeries a year, 18 of 35, or 51.4 percent, had a complete response, defined as no surgery in the 12 months after treatment. Papzimeos is given as four subcutaneous injections over 12 weeks.
The obvious temptation is to put 51.4 percent beside 27 percent and declare a winner. That would be a mistake. The products differ in vector, route, evaluable cohort and regulatory path. Voceryq uses plasmid DNA; Papzimeos uses an adenoviral vector. Voceryq is intramuscular with electroporation; Papzimeos is subcutaneous. The evaluable cohorts were 26 and 35 patients. Voceryq's approval is explicitly accelerated. The trials were separate single-arm studies with different entry criteria, so the gap between the numbers is a reason for scrutiny, not a ranking.
Both studies used a surgery-free year as success, and neither has a randomized comparison yet. For a disease that has been managed almost entirely in the operating room, two immunotherapy options in about 14 months is genuine progress. It is also a reminder that progress can arrive as a choice between imperfect data sets rather than as a clean answer.
Safety and access
The most common adverse reactions, each above 5 percent, were injection site reactions, headache, fatigue, hypertension, nausea and dizziness. Inovio said most treatment-related reactions were grade 1 or 2. Electroporation can cause brief muscle contractions, transient bleeding at the site and vasovagal reactions. The safety conditions described include observation for at least 30 minutes after treatment, and use is to be avoided with ipsilateral implanted defibrillators or pacemakers, metal implants or skin abnormalities at the site.
Availability will not be instant. Inovio expects ordering and shipping in about 60 days and a full launch in the first quarter of 2027. The approval covers adults, not children; pediatric RRP is outside the indication. Otolaryngologists will therefore have two immunotherapy options to discuss with adults who need frequent excisions, but the practical conversation will include the confirmatory trial, the delivery burden and the absence of head-to-head data.
The next checkpoints are concrete: the draft confirmatory protocol by the end of 2026, final alignment by mid-2027, and the launch in early 2027. Until those arrive, the 27 percent belongs with its confidence interval, its small denominator and its surrogate endpoint, not in a slogan.